Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
NCT ID: NCT00159640
Last Updated: 2007-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
315 participants
INTERVENTIONAL
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PD-217,014
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients at screening must have a score \>=40 mm on the pain visual analogue scale.
Exclusion Criteria
* Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
* Patients with abnormal electrocardiogram.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Warrawong, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Pfizer Investigational Site
Kippa-Ring, Queensland, Australia
Pfizer Investigational Site
Maroochydore, Queensland, Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Woodville, , Australia
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
CZ-Praha 8, , Czechia
Pfizer Investigational Site
České Budějovice, , Czechia
Pfizer Investigational Site
Pilsen, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Arnhem, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Kampen, , Netherlands
Pfizer Investigational Site
Roosendaal, , Netherlands
Pfizer Investigational Site
Rotterdam, , Netherlands
Pfizer Investigational Site
Stadskanaal, , Netherlands
Pfizer Investigational Site
Granada, Granada, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Málaga, MALAGA, Spain
Pfizer Investigational Site
Seville, SEVILLA, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Portsmouth, Hants, United Kingdom
Pfizer Investigational Site
Northampton, Northants, United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A4451006
Identifier Type: -
Identifier Source: org_study_id